Product Description
a synthetic TLR4 agonist (Sourced from: https://pubmed.ncbi.nlm.nih.gov/32739049/)
Mechanisms of Action: TLR4 Agonist
Novel Mechanism: Yes
Modality: Large Molecule
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: GSK
Company Location: BRENTFORD MIDDLESEX X0 TW8 9GS
Company CEO: Emma Walmsley
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Oncology Solid Tumor Unspecified|Oncology Unspecified|Healthy Volunteers
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT03447314 |
NCT03447314 | P1 |
Completed |
Oncology Solid Tumor Unspecified |
2020-07-01 |
88% |
2022-04-27 |
|
NCT02798978 |
NCT02798978 | P1 |
Completed |
Oncology Unspecified|Healthy Volunteers |
2017-10-13 |
2019-03-20 |
Treatments |